| Title |
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
|
|---|---|
| Published in |
PLOS ONE, October 2009
|
| DOI | 10.1371/journal.pone.0007287 |
| Pubmed ID | |
| Authors |
Andrea Sartore-Bianchi, Federica Di Nicolantonio, Michele Nichelatti, Francesca Molinari, Sara De Dosso, Piercarlo Saletti, Miriam Martini, Tiziana Cipani, Giovanna Marrapese, Luca Mazzucchelli, Simona Lamba, Silvio Veronese, Milo Frattini, Alberto Bardelli, Salvatore Siena |
| Abstract |
KRAS mutations occur in 35-45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been found to give rise to resistance. We present a comprehensive analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression in mCRC patients treated with cetuximab or panitumumab, with the aim of clarifying the relative contribution of these molecular alterations to resistance. |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 2% |
| Netherlands | 1 | <1% |
| Ireland | 1 | <1% |
| United Kingdom | 1 | <1% |
| India | 1 | <1% |
| Spain | 1 | <1% |
| Romania | 1 | <1% |
| Unknown | 129 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 26 | 19% |
| Researcher | 23 | 17% |
| Other | 14 | 10% |
| Student > Postgraduate | 13 | 9% |
| Student > Master | 12 | 9% |
| Other | 35 | 25% |
| Unknown | 15 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 40% |
| Agricultural and Biological Sciences | 31 | 22% |
| Biochemistry, Genetics and Molecular Biology | 13 | 9% |
| Chemistry | 4 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Other | 10 | 7% |
| Unknown | 22 | 16% |